Ikuo Hirano
Gastroenterology · Chicago, ILNPI 1538195185
Payments from drug & device makers
Across 348 payments — averaging $5255.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$490K
- Bristol Myers Squibb$390K
- Takeda Pharmaceuticals U.S.A., Inc.$261K
- Shire North American Group Inc$133K
- AstraZeneca$129K
- Sanofi$122K
- plus $304K from 12 others
Across 118 payments — averaging $536.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$58K
- Bristol Myers Squibb$3K
- Pfizer$3K
What the payments were for
- Consulting fees$258,08356%
- Speaking & faculty fees$157,76335%
- Travel & lodging$36,8868%
- Food & beverage$4,1051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 34 | $490,077 |
| Bristol Myers Squibb | 14 | $389,949 |
| Takeda Pharmaceuticals U.S.A., Inc. | 51 | $260,732 |
| Shire North American Group Inc | 21 | $133,066 |
| AstraZeneca | 14 | $128,879 |
| Sanofi | 41 | $122,016 |
| Regeneron Healthcare Solutions, Inc. | 98 | $120,049 |
| Astrazeneca UK Limited | 7 | $70,126 |
| Pfizer(2 entities) | 12 | $43,913 |
| Adare Pharmaceuticals, Inc. | 25 | $22,963 |
| Sanofi-aventis U.S. LLC | 3 | $16,824 |
| E.r. Squibb & Sons, L.L.C. | 7 | $13,423 |
| Phathom Pharmaceuticals, Inc. | 10 | $8,128 |
| Boston Scientific | 5 | $4,533 |
| AbbVie | 3 | $1,850 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $1,200 |
| Astrazeneca AB | 1 | $669 |
| GSK | 1 | $650 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$250,297
- FASENRA$73,796
- EOHILIA$11,620
- VOQUEZNA$7,000
- Ozanimod$6,442
- VOQUEZNA TRIPLE PAK$6,000
- VOQUEZNA DUAL PAK$6,000
- CRE$1,700
- RADIAL JAW$1,688
- WALLFLEX$850
- VELSIPITY$500
- SPYGLASS$296
How this compares
$1,829,047 in reported general payments places this provider in the 95th percentile of 787 gastroenterology providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 77 | $1,356 |
| Pantoprazole Sodium | 15 | $374 |
| Famotidine | 14 | $81 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Chicago
- David RubinChicago$3.6M
- Stephen HanauerChicago$2.9M
- Parambir DulaiChicago$2.2M
- Steven FlammChicago$1.6M
- Darren BrennerChicago$1.1M
- Russell CohenChicago$985K
- Mary RinellaChicago$938K
- Emanuelle BellaguardaChicago$868K
- Saurabh KapurChicago$867K
- Benjamin LevyChicago$759K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.